Financial report
For the six months ended 30 June 2021 (unaudited)
|
|
|
|
|
|
kEUR |
Note |
H1 2021 |
H1 2020 |
|
|
|
|
|
|
Revenue |
4 |
135,136 |
87,808 |
|
Other operating income |
|
2,936 |
619 |
|
Total income |
|
138,072 |
88,427 |
|
|
|
|
|
|
Cost of sales |
|
-86,839 |
-64,327 |
|
Gross profit |
|
51,233 |
24,100 |
|
|
|
|
|
|
Marketing and sales expenses |
|
-2,133 |
-1,791 |
|
Research expenses |
|
-696 |
-599 |
|
General and administrative expenses |
|
-17,601 |
-11,550 |
|
Total operating expenses |
|
-20,430 |
-13,940 |
|
|
|
|
|
|
Operating result |
|
30,803 |
10,160 |
|
Financial income |
|
6 |
44 |
|
Financial expenses |
|
-1,282 |
-904 |
|
Total financial result |
|
-1,276 |
-860 |
|
|
|
|
|
|
Result before income taxes |
|
29,527 |
9,300 |
|
Income tax charges |
|
-4,904 |
-1,469 |
|
|
|
|
|
|
Result for the period |
|
24,623 |
7,831 |
|
Attributable to shareholders of PolyPeptide Group AG |
|
24,623 |
7,831 |
|
|
|
|
|
|
Result for the period |
|
24,623 |
7,831 |
|
|
|
|
|
|
Earnings per share in EUR, basic |
|
0.79 |
0.26 |
|
Earnings per share in EUR, diluted |
|
0.79 |
0.26 |